Wockhardt Limited (IN:WOCKPHARMA)
:WOCKPHARMA
Want to see IN:WOCKPHARMA full AI Analyst Report?
Top Page
Wockhardt Limited
(WOCKPHARMA)
Select Model
Select Model
Rating:54Neutral
Price Target:
₹1,577.00
▲(12.20% Upside)
Action:Reiterated
Date:05/06/26
The score is driven primarily by a rebuilding but still inconsistent financial profile (profitability and cash-flow volatility), partially supported by strong technical momentum. A very high P/E valuation is a major offset and keeps the overall score in the mid-range despite the recovery signals.
Positive Factors
Return to profitability & revenue recovery
A return to net profitability alongside ~12% top-line growth signals the company has stabilized core sales and can generate earnings again. Over 2–6 months this supports reinvestment in products, reduces insolvency risk, and improves ability to service obligations if earnings persistence continues.
Negative Factors
Volatile cash generation
Uneven conversion of earnings into cash—recent positive OCF but very modest and falling FCF—implies limited internal funding for growth or debt reduction. Over months this raises refinancing and investment risk, and restricts ability to consistently fund regulatory or capacity investments.
Read all positive and negative factors
Positive Factors
Negative Factors
Return to profitability & revenue recovery
A return to net profitability alongside ~12% top-line growth signals the company has stabilized core sales and can generate earnings again. Over 2–6 months this supports reinvestment in products, reduces insolvency risk, and improves ability to service obligations if earnings persistence continues.
Read all positive factors
Wockhardt Limited (WOCKPHARMA) vs. iShares MSCI India ETF (INDA)
Market Cap
₹261.81B
Dividend YieldN/A
Average Volume (3M)24.00K
Price to Earnings (P/E)28.7
Beta (1Y)1.50
Revenue Growth11.99%
EPS GrowthN/A
CountryIN
Employees2,386
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-1.39
Shares Outstanding162,485,570
10 Day Avg. Volume15,364
30 Day Avg. Volume24,000
Financial Highlights & Ratios
PEG Ratio-0.17
Price to Book (P/B)3.86
Price to Sales (P/S)5.66
P/FCF Ratio298.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Wockhardt Limited Business Overview & Revenue Model
Company Description
Wockhardt Limited, a pharmaceutical and biotechnology company, manufactures and markets active pharmaceutical ingredients, formulations, bio-similars, and vaccines in India, the United States, the United Kingdom, Ireland, Mexico, Russia, and inter...
How the Company Makes Money
Wockhardt makes money primarily by selling pharmaceutical products and related healthcare offerings. Key revenue streams typically include (1) sales of finished-dose formulations (branded and/or generic) in India and international markets through ...
Wockhardt Limited Financial Statement Overview
Summary
Income Statement
56
Neutral
Balance Sheet
60
Neutral
Cash Flow
48
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 30.07B | 33.73B | 30.35B | 28.30B | 26.57B | 32.30B |
| Gross Profit | 16.72B | 12.89B | 18.26B | 15.98B | 14.85B | 18.81B |
| EBITDA | 4.53B | 6.30B | 3.60B | 1.38B | 420.00M | 2.26B |
| Net Income | -230.00M | 2.13B | -470.00M | -4.63B | -5.59B | -2.44B |
Balance Sheet | ||||||
| Total Assets | 85.33B | 86.15B | 81.35B | 76.49B | 76.83B | 82.43B |
| Cash, Cash Equivalents and Short-Term Investments | 9.30B | 6.62B | 6.13B | 5.23B | 1.50B | 3.79B |
| Total Debt | 24.56B | 22.33B | 20.21B | 23.56B | 21.84B | 21.98B |
| Total Liabilities | 36.57B | 33.34B | 34.78B | 39.87B | 40.21B | 40.41B |
| Stockholders Equity | 45.67B | 49.40B | 43.53B | 33.59B | 33.54B | 38.49B |
Cash Flow | ||||||
| Free Cash Flow | 1.19B | 640.00M | -2.64B | 30.00M | -560.00M | 2.01B |
| Operating Cash Flow | 1.89B | 2.00B | -220.00M | 2.19B | 1.53B | 4.13B |
| Investing Cash Flow | -4.17B | -2.75B | -7.83B | -1.37B | -1.25B | -2.01B |
| Financing Cash Flow | 2.97B | 1.41B | 4.09B | 3.34B | -3.15B | -710.00M |
Wockhardt Limited Technical Analysis
Positive
1405.55
Price Trends
1369.50
Positive
1383.37
Positive
1407.00
Positive
Market Momentum
64.19
Positive
63.97
Neutral
32.02
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:WOCKPHARMA, the sentiment is Positive. The current price of 1405.55 is below the 20-day moving average (MA) of 1516.64, above the 50-day MA of 1369.50, and below the 200-day MA of 1407.00, indicating a bullish trend. The MACD of 64.19 indicates Positive momentum. The RSI at 63.97 is Neutral, neither overbought nor oversold. The STOCH value of 32.02 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:WOCKPHARMA.
Wockhardt Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | ₹881.60B | 18.87 | ― | 0.33% | 7.31% | 0.34% | |
73 Outperform | ₹417.59B | 27.58 | ― | 0.28% | 8.92% | 24.73% | |
72 Outperform | ₹650.28B | 25.97 | ― | 0.80% | 11.73% | 10.02% | |
67 Neutral | ₹1.10T | 24.38 | ― | 0.63% | 3.19% | -24.26% | |
54 Neutral | ₹261.81B | 28.73 | ― | ― | 11.99% | ― | |
53 Neutral | ₹670.97B | 35.61 | ― | 0.24% | 25.44% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:WOCKPHARMA
Wockhardt Limited
1,611.30
270.90
20.21%
IN:ALKEM
Alkem Laboratories Ltd.
5,438.70
113.32
2.13%
IN:AUROPHARMA
Aurobindo Pharma Ltd
1,517.90
318.45
26.55%
IN:DRREDDY
Dr. Reddy's Laboratories Ltd.
1,321.90
104.87
8.62%
IN:GLENMARK
Glenmark Pharmaceuticals Limited
2,377.65
941.43
65.55%
IN:IPCALAB
IPCA Laboratories Limited
1,646.25
177.84
12.11%
Wockhardt Limited Corporate Events
Wockhardt Clears FY26 Results With Clean Audit, Plans Fundraising Mandate
May 4, 2026
Wockhardt Limited’s board has approved the audited standalone and consolidated financial results for the quarter and full year ended 31 March 2026, with the statutory auditors issuing an unmodified opinion on the accounts. The clean audit op...
Wockhardt Clears FY26 Results With Clean Audit, Plans Flexible Fund-Raising
May 4, 2026
Wockhardt Limited’s board has approved the audited standalone and consolidated financial results for the quarter and financial year ended 31 March 2026. The statutory auditors, MSKC Associates LLP, have issued an unmodified opinion, indicat...
Wockhardt Swings to Profit as FY26 Revenue and EBITDA Surge
May 4, 2026
Wockhardt Limited, the pharmaceutical and biotechnology major, has reported a strong turnaround in profitability for the quarter and financial year ended 31 March 2026, driven by robust revenue and EBITDA growth. The company posted profit before t...
Wockhardt Publishes SEBI-Mandated Notice on Physical Share Transfer Window
Apr 18, 2026
Wockhardt Limited has notified the stock exchanges that it has published a newspaper advertisement regarding a special SEBI-mandated window for re-lodgment of share transfer requests for shares held in physical form. The company has also made this...
Wockhardt Opens SEBI-Mandated Window for Transfer of Physical Shares
Feb 20, 2026
Wockhardt Limited has informed stock exchanges that it has published a newspaper advertisement announcing a special window for re-lodgement of transfer requests for physical shares. The initiative follows a recent SEBI circular aimed at easing inv...
Wockhardt earns independent ‘Aspiring’ ESG rating for 2025
Feb 19, 2026
Wockhardt Limited has been assigned an overall ESG score of 65, rated as “Aspiring,” for 2025 by NSE Sustainability Ratings and Analytics, a SEBI-registered ESG rating provider. The assessment, based solely on public disclosures and in...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.